Angelika M Vollmar Selected Research

Leukemia

1/2021	Small molecule inhibitors of the mitochondrial ClpXP protease possess cytostatic potential and re-sensitize chemo-resistant cancers.
5/2005	Cephalostatin 1 inactivates Bcl-2 by hyperphosphorylation independent of M-phase arrest and DNA damage.
12/2003	Cephalostatin 1 selectively triggers the release of Smac/DIABLO and subsequent apoptosis that is characterized by an increased density of the mitochondrial matrix.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Angelika M Vollmar Research Topics

Disease

52	Neoplasms (Cancer) 01/2022 - 02/2004
9	Reperfusion Injury 10/2009 - 01/2002
8	Neoplasm Metastasis (Metastasis) 01/2018 - 09/2010
8	Ischemia 10/2009 - 01/2002
6	Breast Neoplasms (Breast Cancer) 07/2015 - 10/2009
6	Inflammation (Inflammations) 10/2011 - 04/2003
4	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 07/2015
4	Cardiovascular Diseases (Cardiovascular Disease) 03/2007 - 10/2002
3	Leukemia 01/2021 - 12/2003
3	Carcinoma (Carcinomatosis) 01/2019 - 09/2010
3	Hypoxia (Hypoxemia) 05/2016 - 03/2011
3	Heart Failure 01/2012 - 01/2007
3	Hepatitis 02/2011 - 02/2003
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2020 - 02/2004
2	Tics (Tic) 11/2017 - 03/2017
2	Edema (Dropsy) 10/2012 - 08/2006
2	Necrosis 07/2011 - 09/2003
2	Hyperplasia 08/2010 - 06/2009
2	Hypertrophy 07/2005 - 10/2002
2	Atherosclerosis 02/2004 - 09/2002
2	Liver Diseases (Liver Disease) 09/2003 - 04/2003
1	Melanoma (Melanoma, Malignant) 01/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020
1	Leukemia L1210 01/2019
1	Blister (Bulla) 12/2016
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 12/2015
1	Ataxia Telangiectasia (Louis Bar Syndrome) 07/2015

Drug/Important Bio-Agent (IBA)

11	Adenosine Triphosphatases (ATPase)IBA 01/2019 - 11/2012
10	Pharmaceutical PreparationsIBA 01/2019 - 01/2007
9	Atrial Natriuretic Factor (ANF)IBA 01/2007 - 01/2002
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2009
5	TubulinIBA 01/2019 - 01/2012
4	CationsIBA 01/2022 - 01/2017
4	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 02/2004
4	pretubulysinIBA 01/2019 - 01/2012
4	Phosphotransferases (Kinase)IBA 07/2015 - 08/2009
4	Concanavalin AIBA 10/2011 - 11/2002
3	Biological ProductsIBA 05/2020 - 10/2009
3	Cyclin-Dependent Kinase 5IBA 01/2019 - 07/2015
3	Vacuolar Proton-Translocating ATPases (V-Type ATPase)IBA 07/2015 - 01/2013
3	Proton Pumps (Proton Pump)IBA 04/2014 - 11/2012
3	p38 Mitogen-Activated Protein KinasesIBA 03/2011 - 08/2002
3	NF-kappa B (NF-kB)IBA 10/2009 - 02/2004
3	cephalostatin IIBA 03/2008 - 12/2003
2	Two-Pore ChannelsIBA 01/2021 - 01/2017
2	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 01/2019
2	LipidsIBA 01/2018 - 02/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2017 - 02/2016
2	Transcription Factors (Transcription Factor)IBA 05/2016 - 02/2004
2	doliculideIBA 01/2016 - 09/2014
2	indirubinIBA 09/2014 - 10/2013
2	Protein Kinases (Protein Kinase)IBA 10/2013 - 11/2007
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 10/2011 - 02/2003
2	RoscovitineIBA 09/2011 - 07/2011
2	Heme Oxygenase-1IBA 03/2011 - 04/2003
2	Propolis (Bee Bread)IBA 03/2011 - 08/2006
2	PolyphenolsIBA 08/2010 - 09/2002
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2009 - 02/2003
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2007 - 02/2005
2	ResveratrolIBA 07/2005 - 10/2002
2	Angiotensin IIIBA 07/2005 - 10/2002
2	Krebs-Henseleit solutionIBA 10/2003 - 09/2003
2	Guanosine Monophosphate (5' Guanylic Acid)IBA 09/2003 - 01/2002
2	Messenger RNA (mRNA)IBA 04/2003 - 01/2002
1	Cadherins (E-Cadherin)IBA 01/2022
1	Melanins (Melanin)IBA 01/2021
1	Monophenol Monooxygenase (Tyrosinase)IBA 01/2021
1	tetrandrineIBA 01/2021
1	FlavonoidsIBA 01/2021
1	Cytostatic AgentsIBA 01/2021
1	EnzymesIBA 01/2021
1	Peptide Hydrolases (Proteases)FDA Link 01/2021
1	ProteomeIBA 01/2020
1	Tigecycline (Tygacil)FDA Link 01/2020
1	Membrane Proteins (Integral Membrane Proteins)IBA 07/2019
1	neocarzilin AIBA 07/2019
1	AntimetabolitesIBA 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	chondramide BIBA 01/2019
1	Small Interfering RNA (siRNA)IBA 01/2019
1	Methotrexate (Mexate)FDA LinkGeneric 01/2019
1	IntegrinsIBA 01/2018
1	archazolid AIBA 11/2017
1	LDL CholesterolIBA 10/2017
1	Cholera ToxinIBA 10/2017
1	Bacterial ToxinsIBA 10/2017
1	CholesterolIBA 02/2017
1	Topoisomerase InhibitorsIBA 01/2017
1	NAADP (nicotinic acid adenine dinucleotide phosphate)IBA 01/2017
1	HydrogelsIBA 12/2016
1	CollagenIBA 12/2016
1	matrigelIBA 12/2016
1	Fibrillar CollagensIBA 12/2016
1	Lipid Bilayers (Lipid Bilayer)IBA 11/2015
1	Lipid NanoparticlesIBA 11/2015
1	IronIBA 07/2015
1	Therapeutic UsesIBA 07/2015

Therapy/Procedure

19	Therapeutics 01/2021 - 09/2011
3	Drug Therapy (Chemotherapy) 01/2021 - 09/2011
2	Immunotherapy 05/2020 - 06/2009